Neuroimaging and CBD for Opioid Use Disorder

Inclusion Criteria: * Individuals between 18 and 65 years old. * Current methadone maintenance in an opioid treatment program with a dose of =/\>40mg for at least 14 days prior to participation and prescribed take-home methadone medication. * Current opioid use disorder (OUD) or OUD in remission while on maintenance therapy with opioid agonist therapy (OAT), as determined by DSM-5 with the M.I.N.I. interview (Mini-International Neuropsychiatric Interview). * Urinary toxicology positive for methadone. Exclusion Criteria: * Non-English speaking. * Court mandate to treatment. * Participation in another pharmacotherapeutic trial in the past 3 months. * Poor physical health (as determined by medical screen) that would make study participation unsafe, or would prevent adherence to study procedures, including a history of cardiac disease, arrhythmias, head trauma, and seizures. * Psychiatric conditions under DSM-5 (examined with the MINI) that would make study participation unsafe or which would prevent adherence to study procedure; examples include: suicidal or homicidal ideation requiring immediate attention, or inadequately-treated mental health disorder (e.g. active psychosis or uncontrolled bipolar disorder). * History of impaired renal function or elevated liver enzymes \>2x the normal at prescreening. * QTc Frederica \>500ms. * Current pregnancy \[determined by positive urine test\] or breastfeeding. * Not using an appropriate method of contraception such as hormonal contr…